Charles R Esther1, Aili L Lazaar2, Elena Bordonali3, Bahjat Qaqish3, Richard C Boucher4. 1. Department of Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: Charles_Esther@med.unc.edu. 2. COPD Discovery Medicine, Respiratory Therapy Area, GlaxoSmithKline, King of Prussia, PA. 3. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC. 4. CF/Pulmonary Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
BACKGROUND: Adenosine and related purines have established roles in inflammation, and elevated airway concentrations are predicted in patients with COPD. However, accurate airway surface purine measurements can be confounded by stimulation of purine release during collection of typical respiratory samples. METHODS: Airway samples were collected noninvasively as exhaled breath condensate (EBC) from 36 healthy nonsmokers (NS group), 28 healthy smokers (S group), and 89 subjects with COPD (29 with GOLD [Global Initiative for Chronic Obstructive Lung Disease] stage II, 29 with GOLD stage III, and 31 with GOLD stage IV) and analyzed with mass spectrometry for adenosine, adenosine monophosphate (AMP), and phenylalanine, plus urea as a dilution marker. Variable dilution of airway secretions in EBC was controlled using ratios to urea, and airway surface concentrations were calculated using EBC to serum urea-based dilution factors. RESULTS: EBC adenosine to urea ratios were similar in NS (0.20 ± 0.21) and S (0.22 ± 0.20) groups but elevated in those with COPD (0.32 ± 0.30, P < .01 vs NS). Adenosine to urea ratios were highest in the most severely affected cohort (GOLD IV, 0.35 ± 0.34, P < .01 vs NS) and negatively correlated with FEV(1) (r = -0.27, P < .01). Elevated AMP to urea ratios were also observed in the COPD group (0.58 ± 0.97 COPD, 0.29 ± 0.35 NS, P < .02), but phenylalanine to urea ratios were similar in all groups. Airway surface adenosine concentrations calculated in a subset of subjects were 3.2 ± 2.7 μM in those with COPD (n = 28) relative to 1.7 ± 1.5 μM in the NS group (n = 16, P < .05). CONCLUSIONS: Airway purines are present on airway surfaces at physiologically significant concentrations, are elevated in COPD, and correlate with markers of COPD severity. Purinergic signaling pathways are potential therapeutic targets in COPD, and EBC purines are potential noninvasive biomarkers.
BACKGROUND:Adenosine and related purines have established roles in inflammation, and elevated airway concentrations are predicted in patients with COPD. However, accurate airway surface purine measurements can be confounded by stimulation of purine release during collection of typical respiratory samples. METHODS: Airway samples were collected noninvasively as exhaled breath condensate (EBC) from 36 healthy nonsmokers (NS group), 28 healthy smokers (S group), and 89 subjects with COPD (29 with GOLD [Global Initiative for Chronic Obstructive Lung Disease] stage II, 29 with GOLD stage III, and 31 with GOLD stage IV) and analyzed with mass spectrometry for adenosine, adenosine monophosphate (AMP), and phenylalanine, plus urea as a dilution marker. Variable dilution of airway secretions in EBC was controlled using ratios to urea, and airway surface concentrations were calculated using EBC to serum urea-based dilution factors. RESULTS:EBCadenosine to urea ratios were similar in NS (0.20 ± 0.21) and S (0.22 ± 0.20) groups but elevated in those with COPD (0.32 ± 0.30, P < .01 vs NS). Adenosine to urea ratios were highest in the most severely affected cohort (GOLD IV, 0.35 ± 0.34, P < .01 vs NS) and negatively correlated with FEV(1) (r = -0.27, P < .01). Elevated AMP to urea ratios were also observed in the COPD group (0.58 ± 0.97 COPD, 0.29 ± 0.35 NS, P < .02), but phenylalanine to urea ratios were similar in all groups. Airway surface adenosine concentrations calculated in a subset of subjects were 3.2 ± 2.7 μM in those with COPD (n = 28) relative to 1.7 ± 1.5 μM in the NS group (n = 16, P < .05). CONCLUSIONS: Airway purines are present on airway surfaces at physiologically significant concentrations, are elevated in COPD, and correlate with markers of COPD severity. Purinergic signaling pathways are potential therapeutic targets in COPD, and EBCpurines are potential noninvasive biomarkers.
Authors: Richard M Effros; Kelly W Hoagland; Mark Bosbous; Daniel Castillo; Bradley Foss; Marshall Dunning; Meir Gare; Wen Lin; Feng Sun Journal: Am J Respir Crit Care Med Date: 2002-03-01 Impact factor: 21.405
Authors: E Huszár; G Vass; E Vizi; Zs Csoma; E Barát; Gy Molnár Világos; I Herjavecz; I Horváth Journal: Eur Respir J Date: 2002-12 Impact factor: 16.671
Authors: Richard M Effros; Richard Casaburi; Janos Porszasz; Edith M Morales; Virender Rehan Journal: Am J Respir Crit Care Med Date: 2012-04-15 Impact factor: 21.405
Authors: Seiko F Okada; Carla M P Ribeiro; Juliana I Sesma; Lucia Seminario-Vidal; Lubna H Abdullah; Catharina van Heusden; Eduardo R Lazarowski; Richard C Boucher Journal: Am J Respir Cell Mol Biol Date: 2013-11 Impact factor: 6.914
Authors: Wayne H Anderson; Raymond D Coakley; Brian Button; Ashley G Henderson; Kirby L Zeman; Neil E Alexis; David B Peden; Eduardo R Lazarowski; C William Davis; Summer Bailey; Fred Fuller; Martha Almond; Bahjat Qaqish; Elena Bordonali; Michael Rubinstein; William D Bennett; Mehmet Kesimer; Richard C Boucher Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405
Authors: Charles R Esther; David B Hill; Brian Button; Shuai Shi; Corey Jania; Elizabeth A Duncan; Claire M Doerschuk; Gang Chen; Sarath Ranganathan; Stephen M Stick; Richard C Boucher Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-01-06 Impact factor: 5.464
Authors: Charles R Esther; Lidija Turkovic; Tim Rosenow; Marianne S Muhlebach; Richard C Boucher; Sarath Ranganathan; Stephen M Stick Journal: Eur Respir J Date: 2016-11-11 Impact factor: 16.671
Authors: Charles R Esther; Bonnie M Olsen; Feng-Chang Lin; Jason Fine; Richard C Boucher Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-01-25 Impact factor: 5.464
Authors: Luis J Garcia-Morales; Ning-Yuan Chen; Tingting Weng; Fayong Luo; Jonathan Davies; Kemly Philip; Kelly A Volcik; Ernestina Melicoff; Javier Amione-Guerra; Raquel R Bunge; Brian A Bruckner; Matthias Loebe; Holger K Eltzschig; Lavannya M Pandit; Michael R Blackburn; Harry Karmouty-Quintana Journal: Am J Respir Cell Mol Biol Date: 2016-04 Impact factor: 6.914